Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 4, 2002, Pages 233-241

  Le Goff, N ^a   Koffel, J C ^a   Vandenschrieck, S ^a   Jung, L ^a   Ubeaud, Genevieve ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Faculty of Pharmacy   (France)

Author keywords

Hepatocytes; Metabolic interaction; Microsomal fractions; Naringenin; Simvastatin

Indexed keywords

NARINGENIN; SIMVASTATIN;

ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CALCULATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG METABOLISM; INTERMETHOD COMPARISON; LIVER CELL; LIVER MICROSOME; MALE; MICHAELIS CONSTANT; NONHUMAN; RAT;

EID: 0036825714     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03192333     Document Type: Article

References (27)

1. Desager J.P. and Horsmans Y. (1996): Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet., 31, 348-371.
2. Pentikainen P.J., Saraheimo M., Schwartz J.I., Amin R.D., Schwartz M.S., Brunner-Ferber F., Rogers J.D. (1992): Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J. Clin. Pharmacol., 32, 136-140.
3. Duggan D.E., Vickers S. (1990): Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab. Rev., 22, 333-362.
4. Vickers S., Duncan C.A., Wu Chen I., Rosegay A., Duggan D.E. (1990): Metabolic disposition studies on simvastatin, a cholesterol lowering prodrug. Drug Metab. Dispos., 18, 138-145.
5. Vickers S., Duncan C.A., Vyas K.P., Kari P.H., Arison B., Prakash S.R., Ramjit H.G., Pitzenberger S.M., Stokker G., Duggan D.E. (1990): In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos., 18, 476-483.
6. Ubeaud G., Hagenbach J., Vandenschrieck S., Jung L., Koffel J.C. (1999): In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci. 65, 1403-1412.
7. Lilja J.J., Kivistö K.T., Neuvoten PJ. (1998): Grapefruit juice-simvastain interaction: effect on serum concentrations of simyastatin, simvastain acid, and HMG-CoA reductase inhibitors. Clin. Pharm. Ther., 64, 477-483.
8. Carlucci G., Mazzeo P., Biordi L., Bologna M. (1992): Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection. J. Pharm. Biomed. Anal., 10, 693-697.
9. Seglen P.O. (1976): Preparation of isolated rat liver cells. Meth. Cell. Biol., 13, 29-83.
10. Dou M., De Souza G., Lacarelle B., Placidi M., Lechesne de la Porte P., Domingo M., Lafont H., Rahmani R. (1992): Thawed human hepatocytes in primary culture. Cryobiology, 29, 454-469.
11. Bradford M.M. (1976): A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72, 248-254.
12. Omura T. and Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem., 239, 2379-2385.
13. Ubeaud G., Schmitt C., Jaeck D., Lave T., Coassolo Ph. (1995). Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica, 25, 1381-1390.
14. Condorcet D. (1996): Transformation and estimating Michaelis-Menten parameters. Abstract in Group Metabolism and Pharmacokinetics, Paris: 13-18.
15. Bourrie M., Meunier V., Berger Y., Fabre G. (1996): Cytochrome P450 isoform inhibitors as a tool for investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 277, 321-332.
16. Kakkar T., Boxenbaum H., Mayersohn M. (1999): Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab. Disp., 27, 756-762.
17. Voet D. and Voet J. (1990):. Rates of enzymatic reaction in Biochemistry, John Wiley Editor, New York: 342-344.
18. Rowland M. and Tozer T.N. (1989): Physiologic concept and kinetics. In: Lea and Febige Editors (2nd Ed). Clinical Pharmacokinetics. Concepts and Applications., Philadelphia:. 103-196.
19. Tang B.K., Kalow W. (1995). Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. Eur. J. Clin. Pharmacol., 47, 449-451.
20. Dixon M. (1953). The determination of enzyme inhibitor constants. Biochem. J., 55, 170-171.
21. Miniscalco A., Lundahl J., Regardh C.G., Edgar B., Eriksson U.G. (1992): Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharm. Exp. Ther., 261, 1195-1198.
22. Bailey D.G., spence J.D., Munoz C., Arnold J.M.O. (1991): Interaction of citrus juice with felodipine and nifedipine. Lancet, 337, 268-269.
23. Soldner A., Christians U., Susanto M., Wacher V.J., Silverman J.A., Benet L.Z. (1999): Grapefruit juice activates P-glycoprotein - mediated drug transport. Pharm. Res., 16, 478-485.
24. Houston J.B. (1994): Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol., 47, 1469-1479.
25. Carlile D.J., Zomorodi K., Houston J.B. (1997): Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver. Studies with induced livers involving Diazepam. Drug Metab. Dispos., 25, 903-911.
26. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones b.C., MacIntyre F., Rance D.J., Wastall P. (1997): The prediction of human pharmacokinetics parameters from preclinical and in vitro metabolism data. J. Pharm. Exp. Ther., 283, 46-58.
27. Bayliss M.K., Bell J.A., Jenner W.N., Park G.R., Wilson K. (1999): Utility of hepatocytes to model species differences in the metabolism of loxitidine and to predict pharmacokinetics parameters in rat, dog and man. Xenobiotica 29, 253-268.